Janssen-Protagonist IL-23R Collaboration

Sexton Riley LLP Represents Janssen in Worldwide Exclusive License and Collaboration Agreement with Protagonist Therapeutics

May 2017

Sexton Riley LLP represented Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, in a worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, Inc. (Protagonist) to develop, manufacture and commercialize PTG-200, a first-in-class, oral interleukin-23 receptor (IL-23R) antagonist drug candidate in development for the treatment of Crohn’s disease and ulcerative colitis (UC).

​The Janssen press release is here.

Recent Posts

See All

Sexton Riley LLP is proud to announce that Julienne Hearn has joined the firm as a partner, as of October 1, 2021. Julienne is a corporate and intellectual property lawyer with extensive experience ad

Sexton Riley LLP Represents Janssen Affiliate Cilag GmbH International in Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab December 2018 ​Sexton Riley LLP